UA26177C2 - METHOD OF PREVENTING ANTI-INFLAMMATORY MEDICINE - Google Patents
METHOD OF PREVENTING ANTI-INFLAMMATORY MEDICINE Download PDFInfo
- Publication number
- UA26177C2 UA26177C2 UA97115452A UA97115452A UA26177C2 UA 26177 C2 UA26177 C2 UA 26177C2 UA 97115452 A UA97115452 A UA 97115452A UA 97115452 A UA97115452 A UA 97115452A UA 26177 C2 UA26177 C2 UA 26177C2
- Authority
- UA
- Ukraine
- Prior art keywords
- inflammatory
- inflammatory medicine
- preventing anti
- raw material
- extract
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title description 3
- 238000000034 method Methods 0.000 title description 2
- 241000283690 Bos taurus Species 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000002826 placenta Anatomy 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 2
- 208000004145 Endometritis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 description 1
- 208000010238 Uterine Inertia Diseases 0.000 description 1
- 206010046763 Uterine atony Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
До отриманого екстракту при постійному перемішуванні додавали консервант із розрахунку 100мл 195 розчину хінозолу в фізіологічному розчині на 1л екстракту. Потім екстракт тканини плаценти витримували 48 годин при 12760.A preservative was added to the obtained extract with constant stirring at the rate of 100 ml of 195 solution of quinosol in physiological solution per 1 liter of extract. Then the placenta tissue extract was kept for 48 hours at 12760.
Утворені в процесі такої операції нерозчинні частини вилучали фільтруванням через фільтр з розміром пор 0,45мМКм.The insoluble parts formed during this operation were removed by filtering through a filter with a pore size of 0.45 mm.
Фільтрат термостатували при 40"С протягом 7 діб, після асептичного фільтрування продукт витримали в герметично закритій посудині протягом З0 діб при 1076.The filtrate was thermostated at 40"C for 7 days, after aseptic filtering, the product was aged in a hermetically sealed vessel for 30 days at 1076.
Після асептичного фільтрування засіб ампулювали.After aseptic filtering, the agent was ampoulated.
Отриманий засіб "Інфламафертин" являє собою прозору солом'яно-жовтого кольору рідину з рН - 5,7 - 6.2, показник заломлення 1,3370 - 1,3383, вміст сухого залишку 28,90 - 29,25мг/мл.The obtained product "Inflamafertin" is a transparent straw-yellow liquid with pH - 5.7 - 6.2, refractive index 1.3370 - 1.3383, content of dry residue 28.90 - 29.25mg/ml.
Приклад 2. При приготуванні свічок протизапальної дії брали одержаний по прикладу 1 розчин в кількості 50гі в ньому емульгували масло какао в кількості 70г при температурі не вище 5076.Example 2. When preparing anti-inflammatory candles, the solution obtained according to example 1 was taken in the amount of 50g and cocoa butter in the amount of 70g was emulsified in it at a temperature not higher than 5076.
Після емульгування масу розлито в форми.After emulsification, the mass is poured into molds.
В експерименті препарат має виражену протизапальну активність при різноманітних шляхах введення та в широкій межі доз і не викликає алергічних реакцій організму.In the experiment, the drug has pronounced anti-inflammatory activity with various routes of administration and in a wide range of doses and does not cause allergic reactions in the body.
Випробування препарату проводили на 240 коровах з клінічним діагнозом атонія матки, катаральний, серозний гнійно-катаральний ендометрит, препарат вводили внутрішньом'язово по 5мл 1 раз на день всім хворим коровам протягом 5 днів.The drug was tested on 240 cows with a clinical diagnosis of uterine atony, catarrhal, serous purulent-catarrhal endometritis, the drug was administered intramuscularly at 5 ml once a day to all sick cows for 5 days.
В контрольній групі корів з аналогічним діагнозом проводили лікування загальноприйнятими ветеринарними препаратами.In the control group, cows with a similar diagnosis were treated with commonly accepted veterinary drugs.
В дослідній групі видужання корів було на 8595 більше, ніж в контрольній групі.In the experimental group, the recovery of cows was 8595 more than in the control group.
Таким чином, особливості способу, що заявляється, визначають властивості препарату, що одержують, які полягають у високій ефективності лікування запальних процесів різноманітної етимології.Thus, the features of the claimed method determine the properties of the resulting drug, which are high efficiency in the treatment of inflammatory processes of various etymologies.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA97115452A UA26177C2 (en) | 1997-11-13 | 1997-11-13 | METHOD OF PREVENTING ANTI-INFLAMMATORY MEDICINE |
| RU97119996/14A RU2128514C1 (en) | 1997-11-13 | 1997-12-02 | Method of anti-inflammatory agent preparing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA97115452A UA26177C2 (en) | 1997-11-13 | 1997-11-13 | METHOD OF PREVENTING ANTI-INFLAMMATORY MEDICINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA26177C2 true UA26177C2 (en) | 1999-06-07 |
Family
ID=21689226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA97115452A UA26177C2 (en) | 1997-11-13 | 1997-11-13 | METHOD OF PREVENTING ANTI-INFLAMMATORY MEDICINE |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2128514C1 (en) |
| UA (1) | UA26177C2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240017012A (en) * | 2021-12-24 | 2024-02-06 | 이에이치제이 아이피 리미티드 | placental composition |
-
1997
- 1997-11-13 UA UA97115452A patent/UA26177C2/en unknown
- 1997-12-02 RU RU97119996/14A patent/RU2128514C1/en active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2128514C1 (en) | 1999-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gye et al. | The poisonous properties of colloidal silica. I: the effects of the parenteral administration of large doses | |
| Whipple et al. | Fibrinogen of the blood as influenced by the liver necrosis of chloroform poisoning | |
| JP2014159455A (en) | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation | |
| EP1984006A1 (en) | Conditioned blood composition and method for its production | |
| DE19916085A1 (en) | Antiviral agent, e.g. for treating HIV infections, comprising autovaccine obtained by heating blood containing viruses and antigens with protein crosslinking agent | |
| DE69532112T2 (en) | USE OF MCP-1 FOR INDUCTION OF Cervical Maturation | |
| KR100314820B1 (en) | Semi-Solid Pharmaceuticals and Manufacturing Method | |
| CN105920044B (en) | Hydra stem cell preparation as well as preparation method and application thereof | |
| Padmanabhan | Experimental induction of cranioschisis aperta and exencephaly after neural tube closure: a rat model | |
| EP2730586B1 (en) | Protein-polypeptide complex obtained from tissues of hoofed livestock embryos, process for preparing same and pharmaceutical composition | |
| UA26177C2 (en) | METHOD OF PREVENTING ANTI-INFLAMMATORY MEDICINE | |
| JPH0450293B2 (en) | ||
| Altermatt et al. | Preparation of Human Temporal Bone for Immunohistochemical Investigation (With 1 color plate) | |
| CN115414424B (en) | Phyllanthus emblica spray for preventing and treating alopecia and promoting hair growth and preparation method thereof | |
| SU741882A1 (en) | Method of producing extract "mammotocin" having oxytotic action | |
| DE10213780A1 (en) | Process and means for the production of therapeutically interesting blood compositions | |
| PENNOCK et al. | Multiple myeloma in a dog | |
| EP0396597A1 (en) | Process for producing a therapeutically active ingredient, in particular for cicatrization or for treatment in geriatry, and a therapeutic preparation containing said active ingredient | |
| US1941900A (en) | Testicular extract and method of making the same | |
| WO2010041972A1 (en) | Peptide placenta extract and a method for producing same | |
| CN107260827B (en) | Compound essential oil for treating retained afterbirth of dairy cow and preparation method thereof | |
| TWI353846B (en) | Pharmaceutical compositions for preventing focal c | |
| EA200000634A1 (en) | METHOD FOR PREPARING MEDICINAL PRODUCTS FROM BRAIN TISSUE OF ANIMAL EMBRYOS AND PHARMACOLOGICAL COMPOSITION BASED ON IT | |
| RU2011378C1 (en) | Method of treating subclinical endometritis in cows | |
| RU2116083C1 (en) | Method of preparing immunoglobulin preparation containing recombinant alpha-2-interferon |